Late recurrence of cervical cancer: a report of 16 cases

Purpose: To analyze the clinical characteristics and outcome of cervical cancer patients presenting late recurrence. Materials and Methods: The medical records of 16 patients who were treated between 1974 and 1999 at the Institution and whose cancer recurred after a five-year disease-free interval were reviewed. Results: Mean time from initial therapy to recurrence was 162.5 months (60 - 360 mean). Smear abnormalities, atypical genital bleeding, abdominal and lumbar pain, and respiratory findings were the most common symptoms and signs associated with late recurrence. Fourteen patients were diagnosed by physical examination. Three of the six patients with local recurrence who were re-irradiated developed a vesico-vaginal fistula. At a median follow-up time of 12.5 months (4-38 mean), 12 patients were alive and the median survival time was 30 months. Conclusions: Cervical cancer patients surviving free of disease after the fifth year post-treatment are still at risk for relapse and in most of them, the recurrence is suspected by clinical examination alone.

Cervical cancer; Late recurrences

[1] Takehara K., Shigemasa K., Sawasaki T., Naito H., Fujii T.: “Recurrence of invasive cervical carcinoma more than 5 years after initial therapy”. Obstet. Gynecol., 2001, 98, 680.

[2] Paunier J.P., Delclos L., Fletcher G.H.: “Causes, time of death and sites of failure in squamous-cell carcinoma of the uterine cervix on intact uterus”. Radiology, 1967, 88, 555.

[3] Candelaria M., Cetina L., de la Garza J., Duenas-Gonzalez A.: “Clinical implications of gemcitabine in the treatment of cervical cancer”. Eur. J. Cancer, 2007, 5 (suppl.), 37.

[4] Brooks R.A., Rader J.S., Dehdashti F., Mutch D.G., Powell M.A., Thaker P.H. et al.: “Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer”. Gynecol. Oncol., 2009, 112, 104.

[5] Bodurka-Bevers D., Morris M., Eifel P.J., Levenback C., Bevers M.W., Lucas K.R., Wharton J.T.: “Posttherapy surveillance of women with cervical cancer: an outcomes analysis”. Gynecol. Oncol., 2000, 78, 187.

[6] Magné N., Chargari C., Vicenzi L., Gillion N., Messai T., Magné J., Bonardel G., Haie-Meder C.: “New trends in the evaluation and treatment of cervix cancer: the role of FDG-PET”. Cancer Treat. Rev., 2008, 34, 671.

[7] Belonoschkin B.: “Recurrence of carcinoma 5 years after cure of irradiated carcinoma of the uterine cervix”. Acta Radiol., 1955, 44, 57.

[8] Bailar J.C. 3rd: “Uterine cancer in Connecticut: Late deaths among 5-year survivors”. J. Natl. Cancer Inst., 1961, 27, 239.

[9] Covington E.E.: “Recurrences of carcinoma of the cervix after 15 years. Report of a 16-year and 24-year local recurrence after irradiation”. Am. J. Obstet. Gynecol., 1963, 87, 471.

[10] McIlhaney J.S. Jr., Kaplan A.L.: “Recurrences of carcinoma of the cervix after ten years”. South Med., 1969, 62, 1119.

[11] Van Herik M., Decker D.G., Lee R.A., Symmonds R.E.: “Late recurrence in carcinoma of the cervix”. Am. J. Obstet. Gynecol., 1970, 108, 1183.

[12] Sakurai H., Mitsuhashi N., Takahashi M., Akimoto T., Muramatsu H., Ishikawa H. et al.: “Analysis of recurrence of squamous cell carcinoma of the uterine cervix after definitive radiation therapy alone: patterns of recurrence, latent periods and prognosis”. Int. J. Radiation Oncol. Biol. Phys., 2001, 50, 1136.

[13] Veronesi U., Cascinelli N., Mariani L. et al.: “Twenty-year followup of a randomized study comparing breast conserving surgery with radical mastectomy for early breast cancer”. N. Engl. J. Med., 2002, 347, 1227.

[14] Disaia P.J., Creasman W.T.: “Invasive cervical cancer”. Clin. Gynecol. Oncol., 1993, 97.

[15] Prempress T., Amornmarn R., Villasanta U., Kwon T., Scott R.: “Retreatment of very late recurrent invasive squamous cell carcinoma of the cervix with irradiation”. Cancer, 1984, 54, 1950.

[16] Hiyama T., Fujimoto I., Hanai A., Oshima A.: “Occurrence of second primary cancers among patients with cervical cancer in Osaka, Japan”. Natl. Cancer Inst. Monogr., 1985, 69, 181.

[17] Pettersson F., Ryberg M., Malker B.: “Second primary cancer after treatment of invasive carcinoma of the uterine cervix, compared with those arising after treatment for in situ carcinomas. An effect of irradiation? A cancer registry study”. Acta Obstet. Gynecol. Scand., 1990, 69, 161.

[18] Grisaru D., Covens A., Chapman B., Shaw P., Colgan T., Murphy J. et al.: “Does histology influence prognosis in patients with early-stage cervical carcinoma?”. Cancer, 2001, 92, 2999.

[19] Eifel P.J., Burke T.W., Morris M., Smith T.L.: “Adenocarcinoma as an independent risk factor for disease recurrence in patients with Stage IB cervical carcinoma”. Gynecol. Oncol., 1995, 59, 38.

[20] Hong J.H., Tsai C.S., Wang C.C., Lai C.H., Chen W.C., Lee S.P. et al.: “Comparison of clinical behaviors and responses to radiation between squamous cell carcinomas and adenocarcinomas/ adenosquamous carcinomas of the cervix”. Chang Gung Med. J., 2000, 23, 396.

[21] Clark G.M., Sledge G.W. Jr., Osborne C.K., McGuire W.L.: “Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients”. J. Clin. Oncol., 1987, 5, 55.

[22] Goto T., Kino N., Shirai T., Fujimura M., Takahashi M., Shiromizu K.: “Late recurrence of invasive cervical cancer: Twenty years’ experience in a single cancer institute”. J. Obstet. Gynaecol., 2005, 31, 514.

[23] Maddox J.E., Moran J.L., Dierker L.J. Jr.: “Late osseous metastasis from carcinoma of the cervix. A suggestion of a 26 year recurrence.” Va Med Mon., 1974, 101, 25.

[24] España L., Martín B., Aragüés R., Chiva C., Oliva B., Andreu D. et al.: “Bcl-x(L)-mediated changes in metabolic pathways of breast cancer cells: from survival in the blood stream to organ-specific metastasis”. Am. J. Pathol., 2005, 167, 1125.

[25] Monk B.J., Sill M.W., McMeekin D.S., Cohn D.E., Ramondetta L.M., Boardman C.H. et al.: “Phase III trial of four cisplatin-containing doublet combinations in Stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study”. J. Clin. Oncol., 2009, 27, 4649.

[26] Coronel J., Cetina L., Candelaria M., González-Fierro A., Arias D., Cantu D. et al.: “Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer”. Med. Oncol., 2009, 26, 210.